MXMeng-Yao Xiong

Meng-Yao Xiong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meng-Yao Xiong has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Baoxue Yang

    Department of Pharmacology, School of Basic Medical Sciences Peking University Beijing China

    1 shared publication
  • Bo-Yang Cai

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China

    1 shared publication
  • Chang-Xiu Qu

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China

    1 shared publication
  • Chao Zhang

    Institute of Brain Science and Brain-inspired Research, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China

    1 shared publication
  • Chenyang Xue

    Department of Immunology and Microbiology, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China

    1 shared publication
  • Fan Yang

    Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Shandong University, Jinan, China

    1 shared publication

Latest Publications

  • Open Access

    Single hormone or synthetic agonist induces Gs/Gicoupling selectivity of EP receptors via distinct binding modes and propagating paths

    by Shen-Ming Huang, Meng-Yao Xiong, Lei Liu, Jianqiang Mu, Ming-Wei Wang, Ying-Li Jia, Kui Cai, Lu Tie, Chao Zhang, Sheng Cao, et al.

    To accomplish concerted physiological reactions, nature has diversified functions of a single hormone at at least two primary levels: 1) Different receptors recognize the same hormone, and 2) different cellular effectors couple to the same hormone–receptor pair [R.P. Xiao,Sci STKE2001, re15 (2001); L. Hein, J. D. Altman, B.K. Kobilka,Nature402, 181–184 (1999); Y. Daaka, L. M. Luttrell, R. J. Lefkowitz,Nature390, 88–91 (1997)]. Not only these questions lie in the heart of hormone actions and receptor signaling but also dissecting mechanisms underlying these questions could offer therapeutic routes for refractory diseases, such as kidney injury (KI) or X-linked nephrogenic diabetes insipidus (NDI). Here, we identified that Gs-biased signaling, but not Giactivation downstream of EP4, showed beneficial effects for both KI and NDI treatments. Notably, by solving Cryo-electron microscope (cryo-EM) structures of EP3-Gi, EP4-Gs, and EP4-Giin complex with endogenous prostaglandin E2(PGE2)or two synthetic agonists and comparing with PGE2-EP2-Gsstructures, we found that unique primary sequences of prostaglandin E2 receptor (EP) receptors and distinct conformational states of the EP4 ligand pocket govern the Gs/Gitransducer coupling selectivity through different structural propagation paths, especially via TM6 and TM7, to generate selective cytoplasmic structural features. In particular, the orientation of the PGE2ω-chain and two distinct pockets encompassing agonist L902688 of EP4 were differentiated by their Gs/Gicoupling ability. Further, we identified common and distinct features of cytoplasmic side of EP receptors for Gs/Gicoupling and provide a structural basis for selective and biased agonist design of EP4 with therapeutic potential.